Iron is essential for cell metabolism and is a constituent of hemoproteins, such as hemoglobin, myoglobin, and cytochrome P450. Consequently, total body iron levels are precisely regulated under normal physiologic conditions. Iron overload can be inherited (genetic) or acquired by receiving numerous blood transfusions, getting iron shots or injections, or consuming high levels of supplemental iron.
Treatment of iron overload includes therapeutic phlebotomy, iron chelation therapy, dietary changes, and treatment for complications. Treatment of iron overload requires phlebotomy, and the frequency is guided by serial measurements of serum ferritin levels and transferrin saturation. Iron avidity can result from over-treatment.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/iron-overload-syndrome-market
The Iron Overload Syndrome Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Iron Overload Syndrome market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Iron Overload Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Iron Overload Syndrome Market Key Facts
-
According to a study by Smith et al. (n.d.), the prevalence of newly diagnosed homozygous hereditary hemochromatosis of 1:459 in the total population or 1:395 in white participants. The prevalence among Caucasian males was 1:330.
-
A study by Crooks et al. (2008), showed that the overall prevalence of hemochromatosis in the UK increased through the decade from 3.62 to 7.8 per 100 000, a 2- fold increase. The most prevalent age group was 40–69 accounting for 64% of overall cases.
-
As per the study conducted by Velati et al. (n.d.), the prevalence of idiopathic hemochromatosis in the study population was 0.2%.
-
Sanchez et al. (2000) detected a high frequency of the C282Y mutation (85.1%) in Spanish HH patients, indicating that this mutation is the most common defect associated with the disease in Spain.
-
According to the National Organization of Rare Disorders (NORD) (n.d.), Ferroportin disease affects males and females in equal numbers. Ferroportin affects individuals of all races and ethnicities. Some researchers believe that ferroportin disease is the most common form of hereditary iron overload after classic (type 1) hemochromatosis.
Key Benefits of Iron Overload Syndrome Market Report
-
The market report provides an in-depth analysis of Iron Overload Syndrome Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Iron Overload Syndrome Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Iron Overload Syndrome current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Iron Overload Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Iron Overload Syndrome Market
Iron Overload Syndrome Market Size is expected to increase during the forecast period owing to the increase in the number of cases of iron overload, along with the expected approval of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Iron Overload Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Iron Overload Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Iron Overload Syndrome Epidemiology
The epidemiology section covers insights about the historical and current Iron Overload Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Iron Overload Syndrome Epidemiology Segmentation
-
Total number of cases of Iron Overload
-
Disease-specific cases of Iron Overload
-
Diagnosed and Treatable Cases of Iron Overload
Iron Overload Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Iron Overload Syndrome market or expected to get launched in the market during the study period. The analysis covers Iron Overload Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Iron Overload Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Request for Sample @ Iron Overload Syndrome Therapeutics Market Assessment
Companies across the globe are diligently working toward the development of novel treatment therapies for Iron Overload Syndrome with a considerable amount of success over the years.
Iron Overload Syndrome companies:
-
Protagonist Therapeutics
-
Novartis Pharmaceuticals
-
AbFero Pharmaceuticals
And others.
Iron Overload Syndrome Therapies covered in the report include:
-
PTG-300
-
SP-420
-
Exjade (Deferasirox)
And many others.
The pipeline for iron overload brings a positive ray of hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market.
Table of Content
1. Key Insights
2. Executive Summary
3. Iron Overload Syndrome Competitive Intelligence Analysis
4. Iron Overload Syndrome Market Overview at a Glance
5. Iron Overload Syndrome Disease Background and Overview
6. Iron Overload Syndrome Patient Journey
7. Iron Overload Syndrome Epidemiology and Patient Population
8. Iron Overload Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Iron Overload Syndrome Unmet Needs
10. Key Endpoints of Iron Overload Syndrome Treatment
11. Iron Overload Syndrome Marketed Products
12. Iron Overload Syndrome Emerging Therapies
13. Iron Overload Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Iron Overload Syndrome Market Outlook (7 major markets)
16. Iron Overload Syndrome Access and Reimbursement Overview
17. KOL Views on the Iron Overload Syndrome Market.
18. Iron Overload Syndrome Market Drivers
19. Iron Overload Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/iron-overload-syndrome-market
Latest Healthcare Blogs
Key Companies in Skin Cancer Market
Skin Cancer today is one of the major causes of mortality, years of life lost, and disability worldwide, which consequently affects the health outcome and the quality of life of the patients and their families. However, some of the key companies are focussing to offer potential treatment options in the Skin Cancer segment such as Bristol Myers Squibb, NantKwest, PellePharm, Medivir AB, Regeneron, and many others.
Cardiac Monitoring Devices Market
As per DelveInsight, the rising incidence of cardiovascular conditions, increasing demand for innovative devices, and technological advancements are expected to drive the growth of the Cardiac Monitoring Devices Market in the coming years. Some of the key companies in the Cardiac Monitoring Devices Market include Medtronic, Boston Scientific, Abbott, GE Healthcare, BIOTRONIK, MicroPort, Nihon Kohden America, SCHILLER, BPL Medical Technologies, ACS Diagnostics, Shenzhen Mindray Bio-Medical Electronics, Lepu Medical Technology, Shree Pacetronix, Metrax GmbH, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/